Compare PXED & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | OBX |
|---|---|---|
| Founded | 1976 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.1M | 839.5M |
| IPO Year | 2025 | 2026 |
| Metric | PXED | OBX |
|---|---|---|
| Price | $23.83 | $14.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $40.75 | $39.00 |
| AVG Volume (30 Days) | 78.4K | ★ 395.2K |
| Earning Date | 11-03-2026 | 11-13-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.56 | N/A |
| Revenue Next Year | $3.25 | N/A |
| P/E Ratio | $14.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.42 | $11.52 |
| 52 Week High | $38.19 | $39.00 |
| Indicator | PXED | OBX |
|---|---|---|
| Relative Strength Index (RSI) | 31.92 | 48.90 |
| Support Level | N/A | $12.16 |
| Resistance Level | $30.79 | $18.21 |
| Average True Range (ATR) | 0.86 | 1.10 |
| MACD | -0.05 | 0.34 |
| Stochastic Oscillator | 10.16 | 87.99 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.